

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.		FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/782,695	10/782,695 02/19/2004		Maria A. Glucksmann	MPI04-002OMNIM	4730
30405	7590	10/25/2006		EXAMINER	
		IARMACEUTICAI	JIANG,	JIANG, DONG	
40 Landsdov CAMBRIDO			ART UNIT	PAPER NUMBER	
Crimbiabol, Mr. V2137				1646	
				DATE MAILED: 10/25/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)	
	10/782,695	GLUCKSMANN ET AL.	
Office Action Summary	Examiner	Art Unit	
	Dong Jiang	1646	
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with the c	correspondence address	
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING D  - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 136(a). In no event, however, may a reply be tir will apply and will expire SIX (6) MONTHS from e, cause the application to become ABANDONE	N. nely filed the mailing date of this communication. ED (35 U.S.C. § 133).	
Status			
1)⊠ Responsive to communication(s) filed on <u>24 J</u>	s action is non-final. ince except for formal matters, pro		
Disposition of Claims			
4) Claim(s) 19-28 is/are pending in the application 4a) Of the above claim(s) is/are withdra 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 19-28 are subject to restriction and/o	wn from consideration.		
9) The specification is objected to by the Examine	er.		
10) The drawing(s) filed on is/are: a) accomplicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Example 11.	cepted or b) objected to by the drawing(s) be held in abeyance. Setion is required if the drawing(s) is ob	e 37 CFR 1.85(a). njected to. See 37 CFR 1.121(d).	
Priority under 35 U.S.C. § 119			
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:  1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority application from the International Burea * See the attached detailed Office action for a list	ts have been received. ts have been received in Applicat prity documents have been receive nu (PCT Rule 17.2(a)).	ion No ed in this National Stage	
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	4) Interview Summary Paper No(s)/Mail D	ate	
<ol> <li>Information Disclosure Statement(s) (PTO/SB/08)</li> <li>Paper No(s)/Mail Date</li> </ol>	5)  Notice of Informal F	ratent Application	

Application/Control Number: 10/782,695

Art Unit: 1646

## **DETAILED ACTION**

Applicant's election without traverse of Group VI invention (represented by the original claim 10) and SEQ ID NO:13-15 filed on 24 July 2006 is acknowledged.

Applicant's preliminary amendment filed on 24 July 2006 is acknowledged and entered. Following the amendment, the original claims 1-18 are canceled, and the new claims 19-28 are added.

Currently, claims 19-28 are pending.

Upon reviewing the new claims, second restriction requirement is warranted.

## Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 19-22, 23 in part, 24-27 and 28 in part, drawn to a method for identifying a compound capable of treating a cellular growth or proliferative disorder, wherein the binding of the test compound to the polypeptide is detected by direct binding or a competition binding assay, classified in class 435, subclass 7.1.
- II. Claims 19-22, 23 in part, 24-27 and 28 in part, drawn to a method for identifying a compound capable of treating a cellular growth or proliferative disorder, wherein the binding of the test compound to the polypeptide is detected by an immunoassay, classified in class 435, subclass 7.1.
- III. Claims 19-22, 23 in part, 24-27 and 28 in part, drawn to a method for identifying a compound capable of treating a cellular growth or proliferative disorder, wherein the binding of the test compound to the polypeptide is detected by a yeast two-hybrid assay, classified in class 435, subclass 6.
- IV. Claims 19-22, 23 in part, 24-27 and 28 in part, drawn to a method for identifying a compound capable of treating a cellular growth or proliferative disorder, wherein the binding of the test compound to the polypeptide is detected by an assay for galactosyltransferase-1 activity, classified in class 435, subclass 7.4.

The inventions are distinct, each from the other because:

Application/Control Number: 10/782,695

Art Unit: 1646

Inventions I-IV are drawn to independent methods, wherein each of the methods has different process steps, different active agents, different starting and ending points, such that they require separate searches as each does not require the other.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification and/or recognized divergent subject matters, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143), and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Application/Control Number: 10/782,695 Page 4

Art Unit: 1646

## Advisory Information

Any inquiry concerning this communication should be directed to Dong Jiang whose telephone number is 571-272-0872. The examiner can normally be reached on Monday - Friday from 9:30 AM to 7:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Nickol, can be reached on 571-272-0835. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Dong Jiang Ph.D Patent Examiner

AU1646 10/4/06